Status and phase
Conditions
Treatments
About
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hurthle cells, poorly differentiated carcinoma). At least one measurable lesion (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response Evaluation Criteria In Solid Tumors(RESCIST) version 1.1);
Disease progression within 14 months before inclusion;
Subjects must be 131I-refractory / resistant as defined by at least one of the following;
main organs function is normal;
Eastern Cooperative Oncology Group(ECOG)Performance Status(PS) :0-2;
An expected survival of ≥ 3 months;
Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug;
Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal